Technical Analysis for HALO - Halozyme Therapeutics, Inc.

Grade Last Price % Change Price Change
F 37.76 -1.72% -0.66
HALO closed down 1.72 percent on Friday, October 15, 2021, on 72 percent of normal volume.
Earnings due: Nov 1
*** please verify all earnings dates ***

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical HALO trend table...

Date Alert Name Type % Chg
180 Bearish Setup Bearish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Oversold Stochastic Weakness 0.00%
Oversold Stochastic Weakness -1.72%
Stochastic Buy Signal Bullish 2.33%
NR7 Range Contraction 2.33%
Lower Bollinger Band Walk Weakness 2.33%
Inside Day Range Contraction 2.33%
Oversold Stochastic Weakness 2.33%
Lower Bollinger Band Walk Weakness 3.25%
Older End-of-Day Signals for HALO ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Halozyme Therapeutics, Inc. Description

Halozyme Therapeutics, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human enzymes. Its research focuses on human enzymes that transiently modify tissue under the skin to facilitate the delivery of injected drugs and fluids, or to alter abnormal tissue structures for clinical benefit. The company's products are based on the Enhanze technology, a patented human recombinant hyaluronidase enzyme that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to increase the dispersion and absorption of other injected drugs; in subcutaneous urography; and to improve resorption of radiopaque agents. The company is also developing Ultrafast Insulin program, a Phase II clinical trial product for the treatment of type 1 and 2 diabetes mellitus; PEGPH20, a new molecular entity that is in Phase II clinical trial for the treatment of solid tumors; and HTI-501, a lysosomal proteinase, which is in Phase 1/2 clinical trial for the treatment of edematous fibrosclerotic panniculopathy. It has collaborative partnerships with F. Hoffmann-La Roche, Ltd and Hoffmann-La Roche, Inc.; Pfizer Inc.; Baxter Healthcare Corporation; ViroPharma Incorporated; and Intrexon Corporation for the development of three product candidates. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Solid Tumors Diabetes Antibodies Monoclonal Antibodies Enzymes Insulin Diabetes Mellitus Clinical Trial Product Intrexon Nicu Halozyme Hoffmann La Roche Hyaluronidase

Is HALO a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 56.4
52 Week Low 27.21
Average Volume 739,810
200-Day Moving Average 43.57
50-Day Moving Average 40.47
20-Day Moving Average 39.38
10-Day Moving Average 38.18
Average True Range 1.27
ADX 20.55
+DI 17.62
-DI 22.15
Chandelier Exit (Long, 3 ATRs) 38.86
Chandelier Exit (Short, 3 ATRs) 40.30
Upper Bollinger Bands 42.56
Lower Bollinger Band 36.20
Percent B (%b) 0.24
BandWidth 16.14
MACD Line -1.00
MACD Signal Line -0.82
MACD Histogram -0.1782
Fundamentals Value
Market Cap 5.1 Billion
Num Shares 135 Million
EPS 0.15
Price-to-Earnings (P/E) Ratio 245.19
Price-to-Sales 28.54
Price-to-Book 55.46
PEG Ratio -2.50
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 39.74
Resistance 3 (R3) 39.94 39.47 39.41
Resistance 2 (R2) 39.47 38.97 39.38 39.30
Resistance 1 (R1) 38.62 38.66 38.39 38.42 39.19
Pivot Point 38.15 38.15 38.04 38.06 38.15
Support 1 (S1) 37.30 37.65 37.07 37.10 36.33
Support 2 (S2) 36.83 37.34 36.74 36.22
Support 3 (S3) 35.98 36.83 36.11
Support 4 (S4) 35.78